IDEAYA Biosciences, Inc. (IDYA)
36.11
+0.05
(+0.14%)
USD |
NASDAQ |
Oct 09, 16:00
35.60
-0.51
(-1.41%)
After-Hours: 20:00
IDEAYA Biosciences Enterprise Value : 2.680B for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 2.680B |
| October 08, 2026 | 2.676B |
| October 07, 2026 | 2.695B |
| October 06, 2026 | 2.731B |
| October 05, 2026 | 2.868B |
| October 02, 2026 | 2.801B |
| October 01, 2026 | 2.844B |
| September 30, 2026 | 2.903B |
| September 29, 2026 | 2.849B |
| September 28, 2026 | 2.884B |
| September 25, 2026 | 2.736B |
| September 24, 2026 | 2.741B |
| September 23, 2026 | 2.811B |
| September 22, 2026 | 3.027B |
| September 21, 2026 | 2.946B |
| September 18, 2026 | 2.902B |
| September 17, 2026 | 2.921B |
| September 16, 2026 | 2.837B |
| September 15, 2026 | 2.830B |
| September 14, 2026 | 2.866B |
| September 11, 2026 | 2.823B |
| September 10, 2026 | 2.810B |
| September 09, 2026 | 2.896B |
| September 08, 2026 | 2.944B |
| September 04, 2026 | 3.042B |
| Date | Value |
|---|---|
| September 03, 2026 | 3.052B |
| September 02, 2026 | 3.072B |
| September 01, 2026 | 3.051B |
| August 31, 2026 | 3.065B |
| August 28, 2026 | 3.066B |
| August 27, 2026 | 3.226B |
| August 26, 2026 | 3.208B |
| August 25, 2026 | 3.294B |
| August 24, 2026 | 3.059B |
| August 21, 2026 | 3.024B |
| August 20, 2026 | 2.970B |
| August 19, 2026 | 2.946B |
| August 18, 2026 | 2.856B |
| August 17, 2026 | 2.722B |
| August 14, 2026 | 2.699B |
| August 13, 2026 | 2.735B |
| August 12, 2026 | 2.762B |
| August 11, 2026 | 2.751B |
| August 10, 2026 | 2.741B |
| August 07, 2026 | 2.768B |
| August 06, 2026 | 2.693B |
| August 05, 2026 | 2.674B |
| August 04, 2026 | 2.680B |
| August 03, 2026 | 2.612B |
| July 31, 2026 | 2.622B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ironwood Pharmaceuticals, Inc. | 948.96M |
| Xencor, Inc. | 1.544B |
| BioMarin Pharmaceutical, Inc. | 13.95B |
| MediciNova, Inc. | 49.52M |
| Viking Therapeutics, Inc. | 2.828B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -112.45M |
| Revenue (Quarterly) | 8.857M |
| Total Expenses (Quarterly) | 121.31M |
| EPS Diluted (Quarterly) | -1.222 |
| Gross Profit Margin (Quarterly) | 87.21% |
| Profit Margin (Quarterly) | -1.27K% |
| Earnings Yield | -5.38% |
| Normalized Earnings Yield | -5.381 |